Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The objective of this analysis was to compare the cost-effectiveness of clinic-based methadone maintenance therapy (MMT) and office-based buprenorphine maintenance therapy (BMT) from the perspective of third-party payers in the United States. The authors used a Markov cost-effectiveness model. A hypothetical cohort of 1000 adult, opioid-dependent patients was modeled over a 1-year time horizon. Patients were allowed to transition between the health states of in opioid dependence treatment and either abusing or not abusing opioids, or to have dropped out of treatment. Probabilities were derived from randomized clinical trials comparing methadone and buprenorphine. Costs included drug and administration, clinic visits, and therapy sessions. Effectiveness outcomes examined were (1) retention in the treatment program and (2) opioid abuse-free weeks. For retention in treatment at 1 year, MMT was more costly ($4,613 vs. $4,155) and more effective (20.3% vs. 15.9%) than BMT, resulting in an incremental cost-effectiveness ratio (ICER) of $10,437 per additional patient retained in treatment. MMT was also more effective than BMT in terms of opioid abuse-free weeks (9.2 vs. 9.1 weeks), resulting in an ICER of $8,515 per opioid abuse-free week gained. One-way sensitivity analyses found costs per week of MMT to have the largest impact on the retention-in-treatment outcome, whereas the probability of dropping out with MMT had the greatest impact on opioid abuse-free weeks. The authors conclude that MMT is cost-effective compared with BMT for the treatment of patients with opioid dependence. However, the treatment of substance abuse is complex, and decision makers should also consider individual patient characteristics when making coverage decisions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Societal costs of prescription opioid abuse, dependence, and misuse in the United States
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01075.x · Cited by 644
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 585
Comparison of buprenorphine and methadone in the treatment of opioid dependence
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 305
Opioid dependence treatment: options in pharmacotherapy
Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903037168 · Cited by 222
Economic Costs of Nonmedical Use of Prescription Opioids
Hansen, R. N., Oster, G., Edelsberg, J., Woody, G. E., & Sullivan, S. D. (2011) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181ff04ca · Cited by 183
Direct Costs of Opioid Abuse in an Insured Population in the United States
White, A. G., Birnbaum, H. G., Mareva, M. N., Daher, M., Vallow, S., Schein, J., & Katz, N. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.6.469 · Cited by 180
Direct Costs of Opioid Abuse in an Insured Population in the United States
WHITE, A. G., BIRNBAUM, H. G., MAREVA, M. N., DAHER, M., VALLOW, S., SCHEIN, J., & KATZ, N. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.10.1188 · Cited by 169
Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00010 · Cited by 131
Barnett, P. G., Zaric, G. S., & Brandeau, M. L. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.96912676.x · Cited by 129
Research works printed but not linked: 8
- MMWR Morb Mort Wkly Rep., 60, 1487
- Baser O, Am J Manag Care., 17, S235
- Connock M, Health Technol Assess., 11, 1
- Strain EC, Am J Psychiatry., 151, 1025
- Substance Abuse and Mental Health Services Administration, Methadone Clinics by County Locations
- Center for Substance Abuse and Treatment, SAMHSA/CSAT Treatment Improvement Protocols.Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
- Center for Substance Abuse and Treatment, Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
- World Health Organization, WHO Collaborative Study on Substitution Therapy of Opioid Dependence and HIV/AIDS
Cited by
Onuoha, E. N., Leff, J. A., Schackman, B. R., McCollister, K. E., Polsky, D. E., & Murphy, S. M. (2021) · Value in Health · doi:10.1016/j.jval.2020.12.023 · Cited by 49
Economic Evaluation in Opioid Modeling: Systematic Review
Beaulieu, É., DiGennaro, C., Stringfellow, E. J., Connolly, A., Hamilton, A. D., Hyder, A., Cerdá, M., Keyes, K. M., & Jalali, M. S. (2020) · Value in Health · doi:10.1016/j.jval.2020.07.013 · Cited by 28
A Systematic Review of Simulation Models to Track and Address the Opioid Crisis
Cerdá, M., Jalali, M. S., Hamilton, A. D., DiGennaro, C., Hyder, A., Santaella-Tenorio, J., Kaur, N., Wang, C., & Keyes, K. M. (2021) · Epidemiologic Reviews · doi:10.1093/epirev/mxab013 · Cited by 27
“…(36, 43, 44, 60, 85), China (114), Canada (83), and the United States (33, 35, 84, 86, 87, 89, 90, 92–94, 115, 118, 63, 119, 64, 69, 73, 76, 78, 80, 81) Opioid misuse was modeled at the local level in many studies ( n = 40; 45%), with researchers looking at dynamics within countries, states, and…”
Carter, J. A., Dammerman, R. S., & Frost, M. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1341416 · Cited by 22
Barbosa, C., Dowd, W. N., & Zarkin, G. A. (2020) · Value in Health · doi:10.1016/j.jval.2020.03.015 · Cited by 16
Metadata
- Authors
- King, J. B., Sainski-Nguyen, A. M., & Bellows, B. K.
- Corresponding author
- King, Jordan B.
- Venue
- Journal of Pain & Palliative Care Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2016-01-02
- Volume
- 30
- Issue
- 1
- Pages
- 55-65
- ISSN
- 1536-0288 (ISSN-L)
- 1536-0539
- OpenAlex
- W2329484547
- Cited by
- 20
- References
- 24
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 1 · 2017: 2
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pain & Palliative Care Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- opioid use disorder, methadone maintenance treatment, office-based opioid treatment, cost-effectiveness, treatment retention, third-party payers
- MeSH terms
- Adult, Ambulatory Care Facilities, Buprenorphine, Cost-Benefit Analysis, Humans, Markov Chains, Methadone, Opioid-Related Disorders, United States, Randomized Controlled Trials as Topic, Opiate Substitution Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.3109/15360288.2015.1135847
- The paper
- King, J. B., Sainski-Nguyen, A. M., & Bellows, B. K. (2016). Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis. Journal of Pain & Palliative Care Pharmacotherapy. https://doi.org/10.3109/15360288.2015.1135847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.